It will be interesting to investigate whether dual treatment of anti-LAG-3 antibodies which strongly block both MHC-II and FGL1 improves anti-tumour immunity compared to monotherapy, or if there are no benefits from inhibiting both ligands. This evidence concerns the gene FGL1 and neoplasm.